You are about to be redirected to Xellia’s global website
We are now redirecting you to our global website, click ‘confirm’ below to continue or ‘cancel’ and we will return you to your previous page.Cancel Confirm
For all general company inquires please send an email to: email@example.com
Xellia Pharmaceuticals has become aware of recruitment scams where fraudulent company representatives are contacting individuals and unauthorized appear to act on behalf of Xellia to offer fake job opportunities. Please note that Xellia’s use of recruitment companies to reach out to potential candidates never involves requests or authorises payment of any kind to process job applications or downloading of software.
If you have been contacted by anyone representing themselves as being from Xellia or on behalf of Xellia and are concerned about their legitimacy, please note that all actual open job positions at Xellia will be shown on our own website, here
If you have experienced any of these recruitment scams, please report to your local authorities. You can find more information on scams, as well as how to report a scam for the United States at https://www.consumer.ftc.gov/articles/0243-job-scams
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use VANCOMYCIN INJECTION, safely and effectively. See full prescribing information for VANCOMYCIN INJECTION.
VANCOMYCIN injection, for intravenous use
Initial U.S. Approval: 1958
RECENT MAJOR CHANGES
Boxed Warning 10/2021
Warnings and Precautions, Severe Dermatologic Reactions (5.5) 5/2021
Warnings and Precautions, Potential Risk of Exposure to Excipients During the First or Second Trimester of Pregnancy (5.1) 10/2021
WARNING: POTENTIAL RISK OF EXPOSURE TO EXCIPIENTS DURING THE FIRST OR SECOND TRIMESTER OF PREGNANCY
See full prescribing information for complete boxed warning.
If use of vancomycin is needed during the first or second trimester of pregnancy, use other available formulations of vancomycin. This formulation of vancomycin injection contains the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA), which resulted in fetal malformations in animal reproduction studies at dose exposures approximately 8 and 32 times, respectively, higher than the exposures at the human equivalent dose (5.1, 8.1).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Injection and other antibacterial drugs, Vancomycin Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.6)DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Vancomycin Injection, USP: Single-dose flexible bags containing 500 mg vancomycin in 100 mL, 750 mg vancomycin in 150 mL, 1 g vancomycin in 200 mL, 1.25 g vancomycin in 250 mL, 1.5 g vancomycin in 300 mL, 1.75 g vancomycin in 350 mL and 2 g vancomycin in 400 mL of liquid. (3)
Hypersensitivity to vancomycin (4)WARNINGS AND PRECAUTIONS
The common adverse reactions are anaphylaxis, “red man syndrome”, acute kidney injury, hearing loss, neutropenia. (6.1)